Brief: Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS from CMS
23/10/2023 11:56
Oct 23 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS GRANTED UNIQUE J-CODE AND
PASS-THROUGH
STATUS FOR BARHEMSYS® FROM CMS
* EAGLE PHARMACEUTICALS-J-CODE IS EFFECTIVE JAN 1, 2024, AND
TRANSITIONAL PASS-THROUGH STATUS BECAME EFFECTIVE OCT 1, 2023,
FACILITATING PATIENT ACCESS
Source text for Eikon: ID:nGNX9hn6HH
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq